Picture of Centessa Pharmaceuticals logo

CNTA Centessa Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Momentum

Relative Strength (%)
1m+14.01%
3m+39.11%
6m+66.28%
1yr+159.26%
Volume Change (%)
10d/3m-23.49%
Price vs... (%)
52w High-2.01%
50d MA+26.63%
200d MA+64.77%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-51.9%
Return on Equity-49.79%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Centessa Pharmaceuticals EPS forecast chart

Profile Summary

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).

Directors

    Last Annual
    December 31st, 2022
    Last Interim
    September 30th, 2023
    Incorporated
    October 26th, 2020
    Public Since
    May 28th, 2021
    No. of Shareholders
    7
    No. of Employees
    75
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Select Market
    Shares in Issue
    97,567,483

    CNTA Share Price Performance

    Upcoming Events for CNTA

    Similar to CNTA

    Picture of 2Seventy Bio logo

    2Seventy Bio

    us flag iconNASDAQ Global Select Market

    Picture of 4D Molecular Therapeutics logo

    4D Molecular Therapeutics

    us flag iconNASDAQ Global Select Market

    Picture of AbCellera Biologics logo

    AbCellera Biologics

    us flag iconNASDAQ Global Select Market

    Picture of AbSci logo

    AbSci

    us flag iconNASDAQ Global Select Market

    Picture of Acadia Pharmaceuticals logo

    Acadia Pharmaceuticals

    us flag iconNASDAQ Global Select Market

    FAQ